Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 0.2% – Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price rose 0.2% on Monday . The company traded as high as $0.25 and last traded at $0.24. Approximately 39,010,846 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 120,864,856 shares. The stock had previously closed at $0.24.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a report on Friday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Up 0.2 %

The business has a fifty day moving average price of $0.26 and a 200 day moving average price of $0.30. The company has a market capitalization of $44.01 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.